Neutralizing activity against Omicron subvariants BA.1, BA.2, and BA.4/5 following the third SARS-CoV-2 vaccination in cancer patients undergoing chemotherapy
Open Access
Abstract
No abstract availableKeywords
Funding Information
- Soonchunhyang University
This publication has 13 references indexed in Scilit:
- Effectiveness of BNT162b2 BA.4/5 bivalent mRNA vaccine against a range of COVID-19 outcomes in a large health system in the USA: a test-negative case–control studyThe Lancet Respiratory Medicine, 2023
- Associations of COVID-19 symptoms with omicron subvariants BA.2 and BA.5, host status, and clinical outcomes in Japan: a registry-based observational studyThe Lancet Infectious Diseases, 2023
- Comparison of antibody response to coronavirus disease 2019 vaccination between patients with solid or hematologic cancer patients undergoing chemotherapyAsia-Pacific Journal of Clinical Oncology, 2023
- Eight-Month Follow-up After the Third Dose of BNT162b2 Vaccine in Healthcare Workers: The Question of a Fourth DoseJournal of Korean Medical Science, 2023
- Effects of Omicron Infection and Changes in Serum Antibody Response to Wild-Type, Delta, and Omicron After a Booster Dose With BNT163b2 Vaccine in Korean Healthcare WorkersJournal of Korean Medical Science, 2023
- A Bivalent Omicron-Containing Booster Vaccine against Covid-19New England Journal of Medicine, 2022
- The effectiveness of COVID-19 vaccines in reducing the incidence, hospitalization, and mortality from COVID-19: A systematic review and meta-analysisFrontiers in Public Health, 2022
- Antibody Response of Heterologous vs Homologous Messenger RNA Vaccine Boosters Against the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant: Interim Results from the PRIBIVAC Study, a Randomized Clinical TrialClinical Infectious Diseases, 2022
- Serologic response following SARS-COV2 vaccination in patients with cancer: a systematic review and meta-analysisJournal of Hematology & Oncology, 2022
- Serum Antibody Response Comparison and Adverse Reaction Analysis in Healthcare Workers Vaccinated with the BNT162b2 or ChAdOx1 COVID-19 VaccineVaccines, 2021